R/R Multiple Myeloma: Review of the CARTITUDE Trial

home / investigator-perspectives / r-r-multiple-myeloma-review-of-the-cartitude-trial

Recent updates from the ASH 2020 annual meeting on the phase 1b/2 CARTITUDE-1 trial for relapsed/refractory multiple myeloma.

Unmet Needs in Triple-Class Refractory Multiple Myeloma

EP. 1: Unmet Needs in Triple-Class Refractory Multiple Myeloma

Targeted Oncology
December 23rd 2020

Deepu Madduri, MD, provides an overview of the treatment landscape for patients with triple-class refractory multiple myeloma.

Watch

BCMA-Targeted CAR T-Cell Therapy for Multiple Myeloma

EP. 2: BCMA-Targeted CAR T-Cell Therapy for Multiple Myeloma

Targeted Oncology
December 23rd 2020

Rationale regarding the use of BCMA-targeted CAR T-cell therapy in relapsed/refractory multiple myeloma.

Watch

ASH 2020 Update: Phase 1b/2 CARTITUDE-1

EP. 3: ASH 2020 Update: Phase 1b/2 CARTITUDE-1

Targeted Oncology
December 23rd 2020

Clinical updates from the phase 1b/2 CARTITUDE-1 study of ciltacabtagene autoleucel (cilta-cel) for relapsed/refractory multiple myeloma. 

Watch

Favorable Safety Data from CARTITUDE-1

EP. 4: Favorable Safety Data from CARTITUDE-1

Targeted Oncology
December 23rd 2020

A review of the favorable safety data from CARTITUDE-1 for relapsed/refractory multiple myeloma. 

Watch

Impressive Responses from Cilta-Cel for RRMM

EP. 5: Impressive Responses from Cilta-Cel for RRMM

Targeted Oncology
December 23rd 2020

Deepu Madduri, MD, details the efficacy data from the phase 1b/2 CARTITUDE-1 study of ciltacabtagene autoleucel (cilta-cel) for relapsed/refractory multiple myeloma. 

Watch

Rapidly Evolving Landscape for R/R Multiple Myeloma

EP. 6: Rapidly Evolving Landscape for R/R Multiple Myeloma

Targeted Oncology
December 23rd 2020

Deepu Madduri, MD, details the efficacy data from the phase 1b/2 CARTITUDE-1 study of ciltacabtagene autoleucel (cilta-cel) for relapsed/refractory multiple myeloma. 

Watch